Cinctive Capital Management LP Alkermes Plc. Transaction History

Cinctive Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $2.13 Million - $2.5 Million	91,738 New	91,738 $2.21 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $2.45 Million - $3.55 Million	-111,484 Reduced 58.45%	79,250 $1.77 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $422,848 - $489,159	16,017 Added 9.17%	190,734 $5.68 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $4.03 Million - $4.89 Million	174,717 New	174,717 $4.6 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $2.15 Million - $3.21 Million	-99,924 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $798,038 - $1.1 Million	34,148 Added 51.92%	99,924 $3.08 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $1.24 Million - $1.65 Million	65,776 New	65,776 $1.61 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Cinctive Capital Management LP with notifications on news.